Marc L Turner
Overview
Explore the profile of Marc L Turner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Troland D, et al.
Nat Med
. 2025 Jan;
PMID: 39794616
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis...
2.
Maiers M, Sullivan S, McClain C, Leonhard-Melief C, Turner M, Turner D
Cytotherapy
. 2024 Dec;
27(3):300-306.
PMID: 39718520
Background: Several countries have either developed or are developing national induced pluripotent stem cell (iPSC) banks of cell lines derived from donors with HLA homozygous genotypes (two identical haplotypes) prevalent...
3.
Zahra S, Turner M
Hum Fertil (Camb)
. 2024 Dec;
28(1):2438650.
PMID: 39648672
Donation of substances of human origin (SoHO) is essential for the treatment of many patients and ranges from the donation of whole organs to the donation of tissue or cell...
4.
Cooper R, Sutherland C, Smith L, Cowan G, Barnett M, Mitchell D, et al.
Front Immunol
. 2024 Jul;
15:1412211.
PMID: 39011042
Adoptive immunotherapy with Epstein-Barr virus (EBV)-specific T cells is an effective treatment for relapsed or refractory EBV-induced post-transplant lymphoproliferative disorders (PTLD) with overall survival rates of up to 69%. EBV-specific...
5.
Cho K, Shi J, Phensy A, Turner M, Sohal V
Nature
. 2023 Apr;
617(7961):548-554.
PMID: 37100905
Changes in patterns of activity within the medial prefrontal cortex enable rodents, non-human primates and humans to update their behaviour to adapt to changes in the environment-for example, during cognitive...
6.
Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Graham C, et al.
BMJ Open
. 2021 Nov;
11(11):e053190.
PMID: 34750149
Introduction: Liver cirrhosis is a growing global healthcare challenge. Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and complications related to portal hypertension. There are no licensed antifibrotic or...
7.
Cooper R, Kowalczuk A, Wilkie G, Vickers M, Turner M, Campbell J, et al.
Clin Exp Immunol
. 2021 Jun;
206(1):68-81.
PMID: 34146397
Adoptive immunotherapy using Epstein-Barr Virus (EBV)-specific T cells is a potentially curative treatment for patients with EBV-related malignancies where other clinical options have proved ineffective. We describe improved good manufacturing...
8.
Ten Ham R, Nievaart J, Hoekman J, Cooper R, Frederix G, Leufkens H, et al.
Cytotherapy
. 2021 Feb;
23(8):730-739.
PMID: 33593688
Background Aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden diseases. Manufacturing development of these innovative products is said to be complex and costly. However, little research is...
9.
Cooper R, Fraser A, Smith L, Burgoyne P, Imlach S, Jarvis L, et al.
Front Immunol
. 2021 Jan;
11:598402.
PMID: 33488592
COVID-19 disease caused by the SARS-CoV-2 virus is characterized by dysregulation of effector T cells and accumulation of exhausted T cells. T cell responses to viruses can be corrected by...
10.
Sullivan S, Fairchild P, Marsh S, Muller C, Turner M, Song J, et al.
Stem Cell Res
. 2020 Nov;
49:102035.
PMID: 33221677
The development of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka and colleagues in 2006 has led to a potential new paradigm in cellular therapeutics, including the possibility of producing...